Opening a window on cerebral cholinergic function
PET imaging of acetylcholinesterase
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Just over two decades ago, PET emerged from the laboratory as a result of advances in radiochemical synthesis, detector physics, and image reconstruction techniques. The initial use of PET in neurology predominantly involved studies of cerebral blood flow (CBF) and glucose metabolism to define functional abnormalities in disease and map normal cognitive processes. Yet one of the greatest potential strengths of PET imaging is the ability to measure substances in the brain that occur in nanomolar concentrations, such as neurotransmitters and their receptors. A particularly good example of PET neurotransmitter system imaging is the use of [18F]-fluorodopa and related compounds to study PD. Such work has resulted in important insights into the natural history and differential diagnosis of PD, its early detection, and development and monitoring of therapy.1,2 In this issue of Neurology, Kuhl et al.3 provide new data on a PET tracer for the quantitative imaging of brain acetylcholinesterase (AChE) activity, illustrating an analogous use of PET to study the cholinergic system in aging and AD.
The importance of acetylcholine in normal memory function has been appreciated for years, as has the fact that depletion of acetylcholine is the primary neurochemical abnormality in AD. To date, brain acetylcholine measurements in AD have been performed postmortem. Although this method has been sufficient to demonstrate the importance of the cholinergic deficit in AD and, indeed, produced the data that led to the first neurochemically specific and efficacious therapy for AD, it has obvious limitations. For this reason, several laboratories have been investigating PET radiotracer methods for studying the cholinergic system in patients. Three general approaches have been used: 1) presynaptic terminals have been studied with derivatives of vesamicol to label the vesicular …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Emily Gilmore and Dr. Rachel Beekman
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s diseaseD.E. Kuhl, R.A. Koeppe, S. Minoshima et al.Neurology, March 01, 1999 -
Articles
Cholinergic dysfunction after traumatic brain injuryPreliminary findings from a PET studyA. Östberg, J. Virta, J.O. Rinne et al.Neurology, March 21, 2011 -
Clinical Implications of Neuroscience Research
Acetylcholine in the cerebral cortexEffects and clinical implicationsEduardo E. Benarroch et al.Neurology, August 16, 2010 -
Articles
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivoJ. C. Klein, C. Eggers, E. Kalbe et al.Neurology, February 24, 2010